Nykode doses first participant in Phase I/II Covid-19 vaccine trial
The trial will analyse the safety, reactogenicity and immunogenicity of T cell-specific/VB10.2210 and the RBD/VB10.2129 vaccines.
Norway
Latest in
Norway
BerGenBio concludes subject enrolment in Phase II AML drug trial
Bemcentinib plus LDAC was found to be efficacious and well-tolerated in relapsed elderly AML patients in a study.
How BerGenBio became a frontrunner in UK hunt for Covid-19 treatment
Norwegian biopharma firm BerGenBio is the first of six companies to have its potential Covid-19 treatment fast-tracked as part of…
ByBerGenBio reports positive results from first stage of NSCLC study
Norwegian biopharmaceutical company BerGenBio has reported positive results from the first stage of a Phase II trial (BGBC008) assessing the…
Deals this week: Trevena, Compugen, Biohaven Pharmaceutical
Trevena plans to raise $175m through a public offering of securities.
Deals this week: Aeglea BioTherapeutics, BerGenBio, Evelo Biosciences
Aeglea BioTherapeutics intends to raise funds for its ongoing research and development (R&D), production and regulatory activities and other purposes.